Gyrolab Generic Anti-AAV Kit supports gene therapy development
Ready-to-use kit from Gyros Protein Technologies enables the detection of binding antibodies against AAV vectors without the need for serotype-specific assays
18 Jun 2024
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and provider of peptide synthesizers, has launched its Gyrolab® Generic Anti-Adeno Associated Virus (AAV) Kit. The new ready-to-use kit facilitates the qualitative assessment of pre-existing binding antibodies against AAV vectors, enabling screening in pre-clinical and clinical settings. The kit supports the identification of pre-existing immunity that may interfere with the efficacy of AAV-based gene therapy delivery.
The kit, designed to detect total binding anti-capsid antibodies against the most commonly used AAV serotypes, assesses pre-existing anti-AAV antibodies, thus streamlining the screening process by eliminating the need for serotype-specific assay development. The kit removes the need for capsid labelling, reducing variability and ensuring reproducible data whilst requiring small quantities of viral capsids, preserving precious drug volumes.
The kit is optimized for use on all Gyrolab systems and expands the utility of the Gyrolab platform into the bioanalytical field of AAV-based gene therapies. Automation with Gyrolab systems reduces variability due to manual pipetting and speeds up workflows by reducing assay development time and generating results within 90 minutes, helping to accelerate the development of novel gene therapies.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>